PETER P. PFREUNDSCHUH - 12 Jul 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
CFO and Treasurer
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
12 Jul 2024
Net transactions value
$0
Form type
4
Filing time
12 Jul 2024, 17:29:54 UTC
Previous filing
08 Jul 2024
Next filing
22 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +46,000 $0.000000 46,000 12 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +170,000 $0.000000 170,000 12 Jul 2024 Common Stock 170,000 $12.47 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSU. The RSUs vest by 1/3 on each of July 12, 2025, July 12, 2026 and July 12, 2027, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.
F3 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on July 12, 2025, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.